A SUBGROUP ANALYSIS OF A PHASE 3, RANDOMIZED TRIAL INVESTIGATING SAFETY AND IMMUNOGENICITY OF V116 IN VACCINE-NAÏVE ADULTS AT INCREASED RISK OF PNEUMOCOCCAL DISEASE (STRIDE-8) (ID 848)

Scott P, Pathirana J, Falk Russell A, Fernsler D, Waleed M, Li J, Buchwald U, Esteves-Jaramillo A, and Platt H, for the STRIDE-8 Study Group. Presented on behalf of the authors by Patel J.

MSD (UK)

This work was previously presented at ISPPD-14 in Copenhagen, Denmark, on 17-21 May 2026

Funding: This project was funded by Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USA

Conflicts of interest: The authors are employees of Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USA and MSD (UK) Limited, London, UK